Pfizer ceases Phase III trial of lung cancer drug

12/30/2009 | Yahoo!

Pfizer has decided to stop the Phase III trial of figitumumab, its drug candidate for lung cancer, after an analysis found that combining the drug with paclitaxel and carboplatin would be unlikely to satisfy the study's primary endpoint. "While these findings are disappointing, Pfizer is committed to using information gained from this study to refine the design of future trials of figitumumab in non-small cell lung cancer," a Pfizer executive said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN